Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres

Código QR

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael Cross, Marcus Allen, Laila Kudsiova, Alison Lansley, Greg Scutt, Lucas Bowler, Samantha Lippett, Selma Stafford, Michael Tarzi, Michael Okorie
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/e099a35244874b35a22cee38c9e33a03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Akihiro Matsubara, et al.
Publicado: (2021)

Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer‐BioNTech)
por: Toshiyuki Sumi, et al.
Publicado: (2021)

Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Rami Alqassieh, et al.
Publicado: (2021)

Efficacy of Pfizer-BioNTech in SARS-CoV-2 Delta cluster
por: Hannah E. Landsberg, MSN, MPH, et al.
Publicado: (2022)

Systemic drug-related intertriginous and flexural exanthema induced by the Pfizer-BioNTech COVID-19 vaccine: A report of 2 cases
por: Josephine Hai, BS, et al.
Publicado: (2021)

Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
por: Edrous Alamer, et al.
Publicado: (2021)

Minimal change nephrotic syndrome four days after the administration of Pfizer‐BioNTech COVID‐19 vaccine—a new side effect or coincidence?
por: Mohammed Abdulgayoom, et al.
Publicado: (2021)

Minimal Change Disease After First Dose of Pfizer-BioNTech COVID-19 Vaccine: A Case Report and Review of Minimal Change Disease Related to COVID-19 Vaccine
por: Jessica Hanna, et al.
Publicado: (2021)

RECURRENT AUTOIMMUNE HEMOLYTIC ANEMIA AFTER MRNA COVID-19 VACCINE (PFIZER-BIONTECH)
por: Fatma YILMAZ, et al.
Publicado: (2021)

A single dose of the Biontech/Pfizer BNT162b2 vaccine protected elderly residents from severe COVID‐19 during a SARS‐coronavirus‐2 outbreak in a senior citizen home in Germany
por: Rolf Schwarzer, et al.
Publicado: (2021)

The Pfizer-BNT162b2 mRNA-based vaccine against SARS-CoV-2 may be responsible for awakening the latency of herpes varicella-zoster virus
por: M.D. Maldonado, et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Esther Saiag, et al.
Publicado: (2021)

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
por: Nicola Silvestris
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Timothy A. Bates, et al.
Publicado: (2021)

Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
por: Yamato Nishiguchi, et al.
Publicado: (2021)

Multisystem Inflammation and Organ Dysfunction After BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccination
por: Benjamin Kahn, BA, et al.
Publicado: (2021)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Rana Shibli, et al.
Publicado: (2021)

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age
por: Krzysztof Lukaszuk, et al.
Publicado: (2021)

BNT162b2 vaccine uptake and effectiveness in UK healthcare workers – a single centre cohort study
por: Tariq Azamgarhi, et al.
Publicado: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Jia Ming Low, et al.
Publicado: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Jing Zou, et al.
Publicado: (2021)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Elvira Baos, et al.
Publicado: (2022)

Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS
por: Domenico Pascucci, et al.
Publicado: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
por: Delphina Gomes, et al.
Publicado: (2021)

A Case of Acute Interstitial Nephritis After Two Doses of the BNT162b2 SARS-CoV-2 Vaccine
por: Mira FS, et al.
Publicado: (2021)

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Davide Ferrari, et al.
Publicado: (2021)

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study
por: Mohammad Shehab, et al.
Publicado: (2021)

Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany
por: Delphina Gomes, et al.
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Waleed H. Mahallawi, et al.
Publicado: (2021)

B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies
por: Federica Pulvirenti, et al.
Publicado: (2021)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Shai Efrati, et al.
Publicado: (2021)

Correspondence Regarding “Tolerability of Coronavirus Disease 2019 Vaccines BNT162b2 and mRNA-1273 in Patients With Thymic Epithelial Tumors”
por: Kazuki Takada, MD, PhD, et al.
Publicado: (2021)

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
por: Hamad Ali, et al.
Publicado: (2021)

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
por: Serge Goldman, et al.
Publicado: (2021)

Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People
por: Julie Demaret, et al.
Publicado: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Kenji Maeda, et al.
Publicado: (2021)

SARS‐CoV‐2 infection shortly after BNT162b2 vaccination results in high anti‐spike antibody levels in nursing home residents and staff
por: Doris Urlaub, et al.
Publicado: (2021)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
por: Chiara Agrati, et al.
Publicado: (2021)

Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
por: Chin-Shern Lau, et al.
Publicado: (2021)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Ilaria Vicenti, et al.
Publicado: (2021)